Pacira BioSciences, Inc. SEC Filings

Pacira BioSciences, Inc. (PCRX) filed a notice of proposed sale of common stock under Form 144. The filer plans to sell 3,040 shares of Pacira common stock through Fidelity Brokerage Services LLC on 08/17/2026 on the NASDAQ market, with an aggregate market value of $70,619.20 for the proposed sale. The shares to be sold were originally acquired from the issuer, including 214 shares purchased on 06/30/2022 through an Employee Stock Purchase Plan (cash) and 2,826 shares acquired on 07/01/2022 through restricted stock vesting as compensation.

State Street Corporation reported beneficial ownership of common stock of Pacira BioSciences, Inc.. State Street and its investment adviser subsidiaries collectively beneficially own 2,059,977 shares of Pacira common stock, representing 5.2% of the outstanding class.

State Street reports no sole voting or dispositive power over Pacira shares. It has shared voting power over 1,944,697 shares and shared dispositive power over 2,059,977 shares, reflecting holdings managed through entities including SSGA Funds Management, Inc. and various State Street Global Advisors affiliates.

Pacira BioSciences, Inc. reported Q2 2026 total revenues of $192,399 (in thousands), mainly from EXPAREL and ZILRETTA, with net income of $4,653 (in thousands) or $0.12 per diluted share, compared with a net loss a year earlier. Results included a $6.4 million discrete tax benefit from reversing a U.K. valuation allowance.

The company agreed to divest its iovera° cryoanalgesia business to Zimmer for up to $140.0 million, including a $70.0 million upfront payment and up to $70.0 million in revenue-based milestones; the deal closed on July 31, 2026, with $73.6 million cash received after adjustments. Cash and cash equivalents rose to $205,875 (in thousands), supported by $83,140 (in thousands) of operating cash flow, while Pacira repurchased $50,448 (in thousands) of stock and repaid $10,000 (in thousands) on its Revolving Credit Facility, ending the quarter with total debt of $363,124 (in thousands).

Pacira BioSciences reported second quarter 2026 total revenue of $192.4 million, up 6% from $181.1 million a year earlier, led by EXPAREL sales of $147.8 million and ZILRETTA sales of $32.6 million. GAAP net income was $4.7 million, or $0.12 per share, compared with a $4.8 million loss in 2025. Non-GAAP net income was $29.5 million and adjusted EBITDA $48.7 million, both below prior-year levels.

The company completed the divestiture of its iovera° business to Zimmer Biomet for up to $140 million, receiving $73.6 million in cash at closing, and ended the quarter with $251.0 million in cash, cash equivalents and investments. Updated 2026 guidance calls for total revenue of $735–$760 million, including EXPAREL sales of $600–$620 million, non-GAAP gross margin of 77–79%, and lower non-GAAP SG&A expense of $310–$330 million. Pacira also highlighted expanded reimbursement for EXPAREL from UnitedHealthcare and continued clinical progress for its gene therapy candidate PCRX-201.

Pacira BioSciences agreed to divest its iovera° handheld cryoanalgesia device business to Zimmer Biomet for up to $140.0 million, consisting of an upfront $70.0 million payment and up to an additional $70.0 million in revenue-based milestones through December 31, 2031.

Milestones pay out in tranches of $18.5 million, $23.5 million or $28.0 million if annual iovera° net revenue reaches $50.0 million, $60.0 million or $70.0 million in any year from 2027 to 2031. About 66 employees, roughly 8% of Pacira’s workforce, are expected to join Zimmer Biomet.

Pacira plans to use upfront net proceeds to strengthen its balance sheet, including paying down its senior secured revolving credit facility, and will collaborate with Zimmer Biomet on the iovera° spasticity program with potential incremental compensation. Closing is subject to customary conditions and is expected in the third quarter of 2026.

Pacira BioSciences director Samit Hirawat received new equity awards. He was granted 6,405 restricted stock units of common stock, which will vest on June 10, 2027 if he remains in continuous service with the company through that date.

He was also granted stock options covering 10,891 shares of common stock at an exercise price of $23.42 per share. These options vest and become exercisable on June 10, 2027, and expire on June 10, 2036. Following these awards, he holds 6,405 common shares and options on 10,891 shares directly.

Pacira BioSciences, Inc. Senior Vice President of Finance Lauren Riker sold 6,115 shares of common stock in an open-market transaction at $23.50 per share. After the sale, she directly held 62,284.242 shares. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 12, 2026.

Pacira BioSciences director Christopher Christie received new equity compensation awards. He was granted 6,405 restricted stock units that vest on June 10, 2027, as long as he remains in continuous service with the company through that date. Each unit represents one share of common stock. He also received a stock option for 10,891 shares of common stock at an exercise price of $23.42 per share, which vests and becomes exercisable on June 10, 2027 and expires on June 10, 2036. Following these awards, Christie directly holds 23,059 shares of Pacira common stock. These are compensation-related grants, not open-market purchases or sales.

Pacira BioSciences director Thomas G. Wiggans received a stock option grant for 32,675 shares of common stock. The option has an exercise price of $23.42 per share and expires on June 10, 2036. One-third of the option vests on the first anniversary of the grant, with the remaining shares vesting in equal monthly installments over the following two years, as long as he remains in continuous service. After this grant, he holds options for 32,675 shares.